PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.59%
Both companies show declining cash positions (-7.59% vs AVXL's -2.45%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Cash + STI yoy ≥ 1.5x AVXL's -2.45%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x AVXL's -21.09%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-8.57%
≥ 1.5x AVXL's -2.17%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-5.56%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.97%
Higher Long-Term Investments Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
≥ 1.5x AVXL's -2.17%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-2.42%
Less than half of AVXL's 4.07%. David Dodd sees a more disciplined AP approach or lower volume.
3.64%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-101.55%
Below half of AVXL's 0.03%. Michael Burry suspects a big gap in pre-sales traction.
-3.64%
Less than half of AVXL's -100.00%. David Dodd sees fewer expansions in other current obligations.
-2.05%
Less than half of AVXL's 13.38%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.51%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.32%
Less than half of AVXL's -99.88%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-0.65%
Less than half of AVXL's 13.38%. David Dodd sees far fewer liability expansions relative to competitor.
3.70%
Above 1.5x AVXL's 0.75%. Michael Burry suspects heavy new equity expansion or dilution.
-2.84%
0.75-0.9x AVXL's -3.59%. Bill Ackman questions if competitor reinvests profits more robustly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.53%
≥ 1.5x AVXL's -3.34%. David Dodd sees stronger capital base growth than competitor.
-8.43%
≥ 1.5x AVXL's -2.17%. David Dodd sees faster overall balance sheet growth than competitor.
0.97%
Higher Total Investments Growth compared to AVXL's zero value, indicating better performance.
-4.43%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
7.68%
Above 1.5x AVXL's 2.45%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.